CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 234 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Vanquix Auto-Injector (Diazepam Injection) 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00319501
NCT00319501Phase 3Completed

A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures

Pfizer·interventional·Posted Apr 27, 2006·Updated Sep 23, 2016

In Brief

A Phase 3 clinical trial evaluating Placebo and Vanquix Auto-Injector (Diazepam Injection) for Seizures and 4 related conditions. Completed, enrolled 234 participants across 86 sites.

Detailed Summary

To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or not under the direct supervision of health care professionals at the time of administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 27, 2006
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 20.2 years ago

Interventions

Placebodrug

Intramuscular autoinjector; administered at onset of an episode

Vanquix Auto-Injector (Diazepam Injection)drug

Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode